ProtaGene

ProtaGene announced a leadership change on October 27, 2026. ProtaGene appointed former Merck KGaA CDMO senior vice president Matthias Bucerius as CEO, effective immediately, to work with its Presidents on timelines, data quality, and analytical science.

What changed

Matthias Bucerius was named Chief Executive Officer.

• Leader: Matthias Bucerius
• Role: Chief Executive Officer
• Effective: Effective immediately
• Announcement date: October 27, 2026

Leadership background

Bucerius, who holds a PhD, previously served as Senior Vice President of the CDMO business at Merck KGaA, where he led multiple drug substance sites through FDA inspections. He also oversaw several life science businesses and commercial organizations across Europe, China, and the US.

The mandate

ProtaGene said Bucerius will work with its Presidents, Roland Moussa and Mike Stump, on three client priorities: predictable timelines, consistently high data quality, and analytical science that accelerates programs. Chairman Martin Blüggel said Bucerius combines commercial leadership with a strong record in quality and compliance.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: ProtaGene leadership announcement.